Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy
Open Access
- 1 November 2010
- journal article
- research article
- Published by Taylor & Francis in Vascular Health and Risk Management
- Vol. 6, 1065-75
Abstract
Peer reviewed article authored by (William Insull Jr, Peter P Toth, H Robert Superko, et al). Read article or submit your manuscript for publishing.Keywords
This publication has 58 references indexed in Scilit:
- Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME StudyJournal of Clinical Lipidology, 2009
- Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best PracticesClinical Chemistry, 2009
- Lipoprotein Management in Patients With Cardiometabolic RiskDiabetes Care, 2008
- Lipoprotein Management in Patients With Cardiometabolic RiskJACC, 2008
- LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study—Implications for LDL managementJournal of Clinical Lipidology, 2007
- Lipoprotein Particle Analysis by Nuclear Magnetic Resonance SpectroscopyClinics In Laboratory Medicine, 2006
- Non–HDL Cholesterol, Apolipoproteins A-I and B100, Standard Lipid Measures, Lipid Ratios, and CRP as Risk Factors for Cardiovascular Disease in WomenJAMA, 2005
- Niacin and cholesterol: role in cardiovascular disease (review)The Journal of Nutritional Biochemistry, 2003
- Smallest LDL Particles Are Most Strongly Related to Coronary Disease Progression in MenArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Is it time to measure apolipoprotein B?Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1990